secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sarepta Therapeutics, Inc. (SRPT)
CIK:        0000873303
Form:       8-K
Filed at:   2022-04-21T23:59:59+00:00
Accession:  0001193125-22-112139
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sarepta amends CEO Ingram's stock option; 33% vests immediately; new targets to 2025
--------------------------------------------------------------------------------

- 33.33% (1,099,890 shares) of performance option vested effective April 19, 2022; remainder eligible through June 26, 2025.
- Unvested portion triggers at stock prices $105.74, $128.65, $155.37, $186.36, requiring relative CAGR vs Biotech Index.
- New one-year holding period on shares acquired upon exercise, except for change in control, death, disability, or certain terminations.
- Change-in-control vesting requires minimum $130/share sale price if within 18 months; else next column applies.
- Company expects significant non-cash accounting charge for the amendment; to be disclosed in upcoming 10-Q.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/873303/000119312522112139/0001193125-22-112139-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/873303/000119312522112139/d329540d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-112139

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer